Restricted accessLetterFirst published online 2013-01
Successful Integrase Inhibitor-Based Highly Active Antiretroviral Therapy for a Multidrug-Class-Resistant HIV Type 1 Group O-Infected Patient in Cameroon
GilksCF, CrowleyS, EkpiniRet al.The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet, 2006; 368,9534:505–510.
2.
WHO: Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. 2011 November 012010.
3.
VallariA, HolzmayerV, HarrisBet al.Confirmation of putative HIV-1 group P in Cameroon. J Virol, 2011; 85,3:1403–1407.
4.
AyoubaA, MauclereP, MartinPMet al.HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis, 2001; 7,3:466–467.
5.
DepatureauxA, CharpentierC, LeozMet al.Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr., Feb.2011; 56,2:139–145.
6.
AghokengAF, Mpoudi-NgoleE, DimodiHet al.Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One, 2009; 4,11:e7702.
7.
GueudinM, SimonF. Plasma RNA viral load in HIV-1 group O infection by real-time PCR. Methods Mol Biol, 2005; 304:221–228.
8.
DescampsD, CollinG, LetourneurFet al.Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses. J Virol, 1997; 71,11:8893–8898.
9.
DierynckI, De MeyerS, LathouwersEet al.In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antivir Ther, 2010; 15,8:1161–1169.
10.
BrizV, GarridoC, PovedaEet al.Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses, 2009; 25,2:225–227.
11.
PovedaE, BarreiroP, RodesB, SorianoV. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses, 2005; 21,6:583–585.
12.
RodesB, de MendozaC, RodgersMet al.Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. AIDS Res Hum Retroviruses, 2005; 21,7:602–607.
